KEYNOTE-042: Should Pembrolizumab Replace Chemo for Broader Population with Adv. NSCLC? (BMIC-038)

KEYNOTE-042: Should Pembrolizumab Replace Chemo for Broader Population with Adv. NSCLC? (BMIC-038)

Dr. Jack West reviews the KEYNOTE-042 trial of pembrolizumab vs. chemo in PD-L1-positive NSCLC, highlighting key findings from the presentation in the Plenary Session at ASCO 2018, clinical implications, & whether it should change practice. Visit http://BeaconMedIC.com for more media & information.